GT Biopharma, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by GT Biopharma, Inc. (GTBP) on September 2, 2026. The Company, incorporated in Delaware and listed on the Nasdaq Capital Market, operates as a fully remote entity effective July 1, 2024. The filing details significant corporate governance actions approved by stockholders on August 14, 2026, and finalized by the Board on August 27, 2026.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on capital structure modifications.
Material Changes
- Elimination of Preferred Stock: The Company filed Certificates of Elimination for Series A through Series K Preferred Stock. All outstanding Series C Preferred Stock was converted on September 2, 2026. No shares of the eliminated series were outstanding immediately prior to filing.
- Reverse Stock Split: A 1-for-25 reverse stock split of Common Stock was authorized. This action is effective as of 12:01 a.m. Eastern Time on September 8, 2026.
- Share Count Reduction: Issued and outstanding Common Stock will decrease from approximately 45,109,497 pre-split shares to approximately 1,804,379 post-split shares.
- Authorized Share Reduction: Total authorized capital stock was reduced from 265,000,000 to 26,500,000 shares, consisting of 25,000,000 Common Stock and 1,500,000 Preferred Stock.
- Adjustment of Derivatives: Conversion prices and exercise prices for outstanding convertible securities, warrants, and stock options will be proportionately adjusted.
Guidance, Outlook, and Risks
The filing does not provide forward-looking financial guidance or management commentary on business operations. Key operational details include:
- Trading Resumption: Trading on a split-adjusted basis commences at market open on September 8, 2026, under the new CUSIP number 36254L 407.
- Fractional Shares: No fractional shares will be issued. Fractional interests will be sold by the transfer agent, with net proceeds distributed pro rata to holders.
- Registration Statements: The Company has amended active registration statements (Forms S-1, S-3, and S-8) to reflect the proportionate reduction in undistributed shares covered by these filings.
Investor Verification Checklist
- Verify the new CUSIP number (36254L 407) for post-split trading on September 8, 2026.
- Confirm the adjusted number of shares held in brokerage accounts following the 1-for-25 split.
- Review the treatment of fractional shares and the timing of cash payments for fractional interests.
- Check the adjusted exercise prices and share counts for any outstanding stock options or warrants.
- Confirm the elimination of all Series A through K Preferred Stock rights and obligations.